Provided is a membrane carrier for a test kit for detecting a substance to be detected in a liquid sample, the membrane carrier including: a flow channel having a detection zone, in which the flow channel has a rough structure A having protrusions, at least in the detection zone, a rough microstructure B is formed on a surface of the protrusion, a silane coupling agent is attached to a surface of the rough microstructure B, and a maximum peak height Rp of a roughness curve of a protrusion at which the rough microstructure B is formed, as measured according to JIS B0601: 2013 using a three-dimensional roughness analysis scanning electron microscope, is equal to or more than 0.005 μm and equal to or less than 10 μm, and an average length RSm of a roughness curve element is equal to or more than 0.01 μm and equal to or less than 15 μm.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

Machine image detection involving a trained classifier is used to detect a result of a test stick diagnostic device configured to detect the presence of an analyte in a test sample. Example implementations include receiving a digital image comprising a depiction of at least a portion of a test stick diagnostic device and applying the digital image to a classifier configured to determine a relative position, relative orientation, and relative scale of the portion of the test stick diagnostic device with respect to the digital image, identify a test result region of the test stick diagnostic device, and detect a test result marking in the test result region of the test stick diagnostic device. An indication of a result of a diagnostic test may be provided based on the detected test result marking.

Test cells with first and second sorbent materials defining a first flow path for a solution, a second flow path distinct from the first flow path for a sample, and a test site with immobilized antigens or antibodies or other ligand-binding molecules located at the junction of the sorbent materials for identifying one or more ligands. In one embodiment, a single highly sensitive immunoassay device is provided that detects the presence in a body fluid sample of two or more COVID-19 (Coronavirus disease 2019) antibodies including immunoglobulin M (IgM) and/or immunoglobulin G (IgG) antibodies to nucleocapsid protein (NP) and spike protein receptor binding domain (RBD), and optionally spike protein S1 subunit (S1) COVID-19 virus antigens. The immunoassay device is sensitive in detecting early infection using IgM antibody detection and continuing infection using IgG antibody detection. Additionally, successful inoculation is distinguished from infection after inoculation by comparing NP and RBD results.

A sensor for selectively capturing a targeted cell type in a fluid includes an engineered surface. The engineered surface includes a substrate, a non-adhesive element disposed on at least a portion of a substrate, and an adhesive element disposed on the substrate. The sensor also includes a flow channel in operative contact with the engineered surface; and a detector configured to detect the targeted cell type captured on the engineered surface. Also described is a method for selectively capturing target cell types using the engineered surface.

An optical biomodule for detecting a disease specific biomarker, utilizing an enhanced fluorescence emission (due to integration of one or more three-dimensional (3-D) protruded structures) in a fluidic container, upon chemical binding of a disease specific biomarker binder with its corresponding disease specific biomarker is disclosed. The three-dimensional (3-D) protruded structure can be coupled with a photonic crystal/metamaterial/metamaterial of Epsilon-Near-Zero (ENZ) of a suitable wavelength range. Furthermore, an enhanced fluorescence emission can be modulated by a synthetic Cas13 protein chemically coupled with a CRISPR RNA (crRNA) and a quenched fluorescent reporter. Alternatively, a suitable synthetic substitute of a synthetic Cas13 protein chemically coupled with a CRISPR RNA (crRNA) containing a targeting sequence can also be utilized.

The present disclosure provides a microfluidic chip, a device and a method for chemiluminescence immunoassay. The microfluidic chip includes a base plate, as well as a first liquid inlet channel, a second liquid inlet channel, a third liquid inlet channel, an immune reaction cell, and a luminescent reaction cell formed on a first surface of the base plate. An outlet end of the immune reaction cell is in communication with a liquid inlet end of the luminescent reaction cell, and a primer is disposed in the immune reaction cell for immobilizing an antigen-antibody complex generated in the immune reaction cell.

We describe assay modules (e.g., assay plates, cartridges, multi-well assay plates, reaction vessels, etc.), processes for their preparation, and method of their use for conducting assays. Reagents may be present in free form or supported on solid phases including the surfaces of compartments (e.g., chambers, channels, flow cells, wells, etc.) in the assay modules or the surface of colloids, beads, or other particulate supports. In particular, dry reagents can be incorporated into the compartments of these assay modules and reconstituted prior to their use in accordance with the assay methods. A desiccant material may be used to maintain and stabilize these reagents in a dry state.

A nanopore-containing substrate includes a substrate, a membrane on the substrate, and at least one nanoscale electronic element disposed on or embedded in the membrane. The membrane defines at least one nanopore. The nanoscale electronic element is aligned with one of the nanopores such that a shortest distance between an edge of the nanoscale electronic element and the edge of the nanopore is less than 50 nm. The nanopores may be formed by etching through a dielectric layer using a solution while applying a voltage to the nanoscale electronic element relative to the solution. The nanopore-containing substrate can be used to detect or sequence a biopolymer, such as a nucleic acid. The nanopore-containing substrate may be used with a biopolymer detection and/or sequencing system.

A method can treat a patient suffering from at least one of fibrosis and a fibrotic disorder. The method includes administering a therapeutically effective amount of an anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, to the patient.